Partnering opportunity

Development of novel class of compounds for eye delivery to stop neurodegeneration in glaucoma

Summary

A French pre-clinical stage start-up develops novel solutions to treat neurodegeneration, a process linked with microtubule disorders. It develops compounds to restore microtubule stability. One application is stopping neurodegeneration of the optic nerve in glaucoma, the leading cause of irreversible blindness. The company seeks partners specialized in biopolymers and/or surface chemistry to develop drug formulation and delivery solutions into the eye under research or technical agreements.

Technical Specification or Expertise Sought

The start-up company is looking for a drug delivery vessel (natural or synthetic biopolymer) for the delivery and sustained release of its compounds into the eye. Ideally the vessel/polymer should be: • inducing minimal or no inflammatory response and should not lead to loss of photoreceptor cells • tested in vivo • result in sustained release of the compound • function as a reservoir to reduce the number of injection The compounds will be coupled to the delivery system and tested in relevant models for validation of the approach.

Partner sought

SMEs and pharma industries with an expertise in biopolymers and/or surface chemistry are being sought for drug formulation. In the context of research agreements and/or technological cooperation, the companies are expected to provide matrices of biopolymers and/ or surface chemistry on which the compounds that modify microtubule biophysical properties of microtubules can be attached for appropriate and efficient drug delivery into the eye.

Description

In view of the ageing population, finding a cure for glaucoma, the first cause of irreversible blindness worldwide, remains a priority challenge of the EU. Glaucoma is the result of neurodegeneration of the ganglionic cells of the optical nerve and is accompanied by an increase of the intra-ocular pressure within the eye cavity. While drugs that stabilize and or reduce intra-ocular pressure are quite efficient, it does not always stop neurodegeneration. In glaucoma models, dissociation of the microtubule associated protein tau from microtubules, was recently shown to be linked to the degenerative process. There is a single molecule on market, brimonidine, which beneficial effects remain controversial. While current pharmaceutical efforts focus on acting on tau itself, therapeutics that target the enzymes modifying the microtubules, have so far never been explored. In turn, the company develops compounds to prevent tau dissociation and restore its binding to microtubules. The solutions developed by the company are therefore unique in the healthcare landscape and open the road to novel class of medication Based on breakthrough discoveries, proprietary technologies and unique expertise, the French company has developed first-in-class compounds that specifically target microtubule modifying enzymes. These compounds regulate the biophysical properties of the microtubule surface to favorize the binding of structural microtubule associated proteins and hence promote neuroprotection. The novel compounds that have been developed are aimed at stopping the process of neurodegeneration within the optic nerve, by targeting microtubule modifications. SMEs and pharma industries specialized in biopolymers and/or surface chemistry are sought to contribute to develop and improve drug formulation and delivery solutions into the eye. The idea is to attach the compounds to matrices that allow efficient drug delivery intravitreally and follow the outcome in appropriate models to obtain proof of concepts. According to the stage of development of the delivery system of the partner, research agreements for co-development or technical agreements in case of use of an existing solution will be made.

Advantages and innovations

Not available

Development stage

Under development/lab tested

Intellectual Property Rights (IPR)

Granted patent or patent application essential


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company